Back to top
more

Align Technology (ALGN)

(Delayed Data from NSDQ)

$136.90 USD

136.90
2,127,825

-2.75 (-1.97%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $136.96 +0.06 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 246)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Align Technology, based in California, manufactures and markets a system of clear aligner therapy, intra-oral scanners and CAD/CAM (computer-aided design and computer-aided manufacturing) digital services used in dentistry, orthodontics, and dental records storage. The clear aligner system corrects malocclusion using nearly invisible and removable appliances that gently move the tooth to a desired final position.

Zacks Equity Research

Abbott (ABT) Launches Radiofrequency Ablation Device in U.S.

by Zacks Equity Research

Abbott (ABT) aims to expand its Neuromodulation portfolio with the latest launch of its radiofrequency ablation device.

Zacks Equity Research

Becton Dickinson (BDX) Buys Medical Business Assets of CUBEX

by Zacks Equity Research

This should further boost BD's (BDX) Medical segment.

Zacks Equity Research

Tivity Health's (TVTY) Shares Fall Despite Q3 Earnings Beat

by Zacks Equity Research

Tivity Health (TVTY) reports solid revenue growth in its Nutrition arm in the third quarter due to strength in Nutrisystem brand DTC.

Zacks Equity Research

HMS Holdings (HMSY) Climbs 7.4% Post In-Line Q3 Earnings

by Zacks Equity Research

HMS Holdings (HMSY) witnessed revenue growth in COB and PI segments in the third quarter.

Zacks Equity Research

Owens & Minor's (OMI) Shares Fall Despite Q3 Earnings Beat

by Zacks Equity Research

Owens & Minor (OMI) reports solid revenue growth in its Global Products arm in the third quarter due to strength in PPE sales.

Zacks Equity Research

AMN Healthcare (AMN) Loses 9.4% Despite Q3 Earnings Beat

by Zacks Equity Research

AMN Healthcare (AMN) gained from Technology and Workforce Solutions segment in the third quarter.

Zacks Equity Research

Glaukos (GKOS) Beats Estimates on Narrower-than-Expected Loss (revised)

by Zacks Equity Research

Glaukos' (GKOS) third-quarter results reflect a rise in revenues and recovery in the U.S. Glaucoma franchise.

Zacks Equity Research

Hill-Rom (HRC) Q4 Earnings, Revenues Top Estimates, Fall Y/Y

by Zacks Equity Research

In Q3, Hill-Rom's (HRC) bed orders and backlog in the United States accelerates with sequential recovery in Patient Support Systems arm.

Zacks Equity Research

Glaukos (GKOS) Gains 11.8% Despite Reporting Loss in Q3

by Zacks Equity Research

Glaukos' (GKOS) third-quarter results reflect rise in revenues and recovery in the U.S. Glaucoma franchise.

Zacks Equity Research

Pfizer (PFE) in Focus: Stock Moves 7.7% Higher

by Zacks Equity Research

Pfizer (PFE) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

Zacks Equity Research

Myriad Genetics' (MYGN) Q1 Earnings & Revenues Top Estimates

by Zacks Equity Research

Myriad Genetics' (MYGN) sales in majority of the operating segments plummeted in the quarter owing to the pandemic-led business challenges.

Zacks Equity Research

Luminex (LMNX) Declines 6.6% as Q3 Earnings Miss Estimates

by Zacks Equity Research

Luminex (LMNX) witnessed total sample-to-answer molecular diagnostics revenue growth in the third quarter.

Zacks Equity Research

CAH vs. ALGN: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

CAH vs. ALGN: Which Stock Is the Better Value Option?

Zacks Equity Research

National Vision (EYE) Q3 Earnings Top Estimates, Margins Up

by Zacks Equity Research

National Vision (EYE) witnesses comparable growth on increased customer transaction in Q3.

Zacks Equity Research

Co-Diagnostics (CODX) to Post Q3 Earnings: What's in Store?

by Zacks Equity Research

Co-Diagnostics' (CODX) third-quarter results are likely to reflect higher COVID-19 test sales.

Zacks Equity Research

Tandem Diabetes (TNDM) Q3 Earnings Miss, '20 Sales View Up

by Zacks Equity Research

Tandem Diabetes' (TNDM) strong domestic pump sales and pump shipments boosted the top line.

Zacks Equity Research

Nevro (NVRO) Rallies 1.3% Despite Delivering Loss in Q3

by Zacks Equity Research

Nevro's (NVRO) domestic and international revenues increased on a year-over-year basis in the third quarter.

Zacks Equity Research

CVS Health (CVS) Q3 Earnings Top Estimates, 2020 View Up

by Zacks Equity Research

CVS Health's (CVS) Q3 pharmacy claims processed rise attributable to strong net new business, partially offset by reduced new therapy prescriptions.

Zacks Equity Research

Zimmer Biomet (ZBH) Q3 Earnings Beat, Gross Margin Contracts

by Zacks Equity Research

Zimmer Biomet (ZBH) registers stronger-than-expected recovery of elective procedures in the third quarter.

Zacks Equity Research

Phibro (PAHC) Q1 Earnings Surpass Estimates, Margins Up

by Zacks Equity Research

Phibro's (PAHC) core Animal Health segment, along with strength in Nutritional Specialties and Vaccines, boosted Q1 performance despite pandemic-led business disruptions.

Zacks Equity Research

LHC Group (LHCG) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

LHC Group's (LHCG) third-quarter results benefit from organic growth in home health as well hospice admissions.

Zacks Equity Research

Cardiovascular Systems' (CSII) Q1 Earnings Top Estimates

by Zacks Equity Research

Cardiovascular Systems (CSII) registers dismal segmental revenues despite gradual recovery in business amid the pandemic.

Zacks Equity Research

Inogen (INGN) Stock Loses 9.2% After Delivering Loss in Q3

by Zacks Equity Research

Inogen (INGN) saw revenue decline within its Sales segment in Q3

Zacks Equity Research

PRA Health (PRAH) Gains 4.3% Following Q3 Earnings Beat

by Zacks Equity Research

PRA Health's (PRAH) Data Solutions and Clinical Research segments put up a strong performance in the third quarter.

Zacks Equity Research

Becton Dickinson (BDX) Earnings Surpass Estimates in Q4

by Zacks Equity Research

Within the United States, Becton Dickinson's (BDX) Diagnostic Systems unit witnessed strong revenue growth in the fiscal fourth quarter.